European Journal of Cancer
Volume 46, Issue 2 , Pages 420-429 , January 2010

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

  • Michele Moschetta

      Affiliations

    • Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Italy
    • ,
  • Giulia Di Pietro

      Affiliations

    • Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Italy
    • ,
  • Roberto Ria

      Affiliations

    • Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Italy
    • ,
  • Antonio Gnoni

      Affiliations

    • Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Italy
    • ,
  • Giuseppe Mangialardi

      Affiliations

    • Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Italy
    • ,
  • Attilio Guarini

      Affiliations

    • Hematology Unit, Institute of Oncology ‘Giovanni Paolo II’, I-70100 Bari, Italy
    • ,
  • Paolo Ditonno

      Affiliations

    • Hematology Unit, ‘Di Venere’ Hospital, I-74100 Bari, Italy
    • ,
  • Pellegrino Musto

      Affiliations

    • Hematology and Bone Marrow Transplantation Unit, Centro di Riferimento Oncologico della Basilicata IRCCS-CROB, I-85028 Rionero in Vulture, Potenza, Italy
    • ,
  • Fiorella D’Auria

      Affiliations

    • Hematology and Bone Marrow Transplantation Unit, Centro di Riferimento Oncologico della Basilicata IRCCS-CROB, I-85028 Rionero in Vulture, Potenza, Italy
    • ,
  • Maria Rosaria Ricciardi

      Affiliations

    • Division of Hematology, Department of Cellular Biotechnologies and Hematology, University ‘La Sapienza’, I-00100 Rome, Italy
    • ,
  • Franco Dammacco

      Affiliations

    • Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Italy
    • ,
  • Domenico Ribatti

      Affiliations

    • Department of Human Anatomy and Histology, University of Bari Medical School, Italy
    • ,
  • Angelo Vacca

      Affiliations

    • Department of Internal Medicine and Clinical Oncology, University of Bari Medical School, Italy
    • Corresponding Author InformationCorresponding author: Department of Internal Medicine and Clinical Oncology, Policlinico – Piazza Giulio Cesare, 11, I-70124 Bari, Italy. Tel.: +39 080 559 34 44; fax: +39 080 559 21 89.

Received 28 July 2009 ,Accepted 15 October 2009.

References 

  1. Kyle RA, Rajkumar SV. Multiple myeloma. New Engl J Med. 2004;351(18):1860–1873
  2. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene. 2006;25(31):4257–4266
  3. Ribatti D, Vacca A. The role of monocytes-macrophages in vasculogenesis in multiple myeloma. Leukemia 2009.
  4. Scavelli C, Nico B, Cirulli T, et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene. 2008;27(5):663–674
  5. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 2007;22(12):1387–1398
  6. Sarkar FH, Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci. 2008;13:2950–2959
  7. Podar K, Shringarpure R, Tai YT, et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004;64(20):7500–7506
  8. Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002;29(6 Suppl 21):33–42.
  9. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66(1):184–191
  10. Scavelli C, Di Pietro G, Cirulli T, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007;6(12 Pt 1):3256–62.
  11. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003;121(5):749–57.
  12. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13(3):300–309
  13. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42(11):1228–1236
  14. Vacca A, Ria R, Semeraro F, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood. 2003;102(9):3340–3348
  15. Coluccia AM, Cirulli T, Neri P, et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood. 2008;112(4):1346–1356
  16. Chou TC, Talalay P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55
  17. Kawasaki K, Watabe T, Sase H, et al. Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells. J Cell Biol. 2008;181(1):131–141
  18. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277(19):16639–16647
  19. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med. 2003;348(26):2609–2617
  20. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105(8):3058–3065
  21. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111(8):3968–3977
  22. Yang HH, Vescio R, Schenkein D, Berenson JR. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341), velcade and melphalan in patients with relapsed or refractory multiple myeloma. Clin Lymphoma. 2003;4(2):119–122
  23. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071–3076
  24. Dhillon S, Lyseng-Williamson KA. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs. 2008;68(4):507–534
  25. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med. 2009;360(7):679–691
  26. Mystakidou K, Katsouda E, Parpa E, Vlahos L. Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid. J Pain Palliat Care Pharmacother. 2005;19(3):41–45
  27. Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer. 2000;88(1):6–14
  28. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 2007;20(4):597–612
  29. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105(4):1383–1395
  30. Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;88(2):176–185
  31. Raikkonen J, Crockett JC, Rogers MJ, Monkkonen H, Auriola S, Monkkonen J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Brit J Pharmacol 2009.
  32. Dunford JE, Kwaasi AA, Rogers MJ, et al. Structure–activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem. 2008;51(7):2187–2195
  33. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005;65(12):4971–4974
  34. Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays. 2007;29(4):356–370
  35. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7(5):1419–1428
  36. Cusack JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61(9):3535–3540
  37. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene. 2002;21(42):6510–6519
  38. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res. 2004;64(18):6511–6523
  39. Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003;22(52):8386–8393
  40. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62(17):4996–5000
  41. Pajonk F, McBride WH. The proteasome in cancer biology and treatment. Radiat Res 2001;156(5 Pt 1):447–59.

PII: S0959-8049(09)00777-1

doi: 10.1016/j.ejca.2009.10.019

European Journal of Cancer
Volume 46, Issue 2 , Pages 420-429 , January 2010

Article Tools

* Image Usage & Resolution